|
The FDA on Aug. 19 approved Axsome Therapeutics’ Auvelity for the treatment of major
depressive disorder in adult patients. The N-methyl D-asparate (NMDA) receptor
antagonist has potential to be groundbreaking — Auvelity can begin to take
effect within a week, compared to up to eight weeks in traditional
antidepressants. Evaluate Pharma estimates the drug will bring in $831
million in revenue by 2026. Auvelity is not the first NMDA receptor agonist
in the depression market basket, however. Johnson & Johnson’s Spravato, a
nasal spray, was approved in August 2020, though it is not a first-line
therapy. For the treatment of major depressive disorder, Spravato currently
holds covered or better status for 62% of lives under the pharmacy benefit,
though just 3% of lives have preferred access to the drug. |
|
SOURCE: MMIT Analytics,
as of 8/24/22, and Evaluate Pharma |
No comments:
Post a Comment